Taysha Gene Therapies (TSHA) Cash from Investing Activities (2020 - 2026)
Taysha Gene Therapies (TSHA) posted Cash from Investing Activities of -$3.0 million for Q1 2026, down 1124.29% sequentially from -$247000.0 in Q4 2025, and down 715.09% YoY from $491631.9 in Q1 2025.
Powered by 
Analysis
Taysha Gene Therapies (TSHA) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Taysha Gene Therapies has reported Cash from Investing Activities for 7 years, with the latest figure at -$3.0 million in Q1 2026.
- Quarterly Cash from Investing Activities fell 715.09% year-over-year to -$3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.3 million (down 448.32% YoY) and the FY2025 annual result came in at -$604000.0, down 66.39% from the prior year.
- Cash from Investing Activities fell to -$3.0 million in Q1 2026 per TSHA's latest filing, from -$247000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $62000.0 in Q2 2025 and troughed at -$11.4 million in Q1 2022.
- A 5-year average of -$2.1 million and a median of -$247000.0 in 2025 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities sank 2039.89% in 2022, then surged 230.0% in 2024.
- Over 5 years, Cash from Investing Activities stood at -$2.4 million in 2022, then soared by 99.58% to -$10000.0 in 2023, then soared by 230.0% to $13000.0 in 2024, then sank by 2000.0% to -$247000.0 in 2025, then tumbled by 1124.29% to -$3.0 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$3.0 million, -$247000.0, and -$48000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Taysha Gene Therapies | 2.06 Bn | 2.06 Bn | - | 1,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1,000.00 |
| Mar 31, 2026 | -3.02 Mn |
| Dec 31, 2025 | -247,000.00 |
| Sep 30, 2025 | -48,000.00 |
| Jun 30, 2025 | 62,000.00 |
| Mar 31, 2025 | -371,000.00 |
| Dec 31, 2024 | 13,000.00 |
| Sep 30, 2024 | -35,000.00 |
| Jun 30, 2024 | -201,000.00 |
| Mar 31, 2024 | -140,000.00 |
| Dec 31, 2023 | -10,000.00 |
| Sep 30, 2023 | -3.49 Mn |
| Jun 30, 2023 | 48,000.00 |
| Mar 31, 2023 | -3.90 Mn |
| Dec 31, 2022 | -2.37 Mn |
| Sep 30, 2022 | -3.02 Mn |
| Jun 30, 2022 | -8.11 Mn |
| Mar 31, 2022 | -11.43 Mn |
| Dec 31, 2021 | -8.52 Mn |
| Sep 30, 2021 | -4.00 Mn |